ID   FIBA_HUMAN              Reviewed;         866 AA.
AC   P02671; A8K3E4; D3DP14; D3DP15; Q4QQH7; Q9BX62; Q9UCH2;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 2.
DT   10-MAY-2017, entry version 218.
DE   RecName: Full=Fibrinogen alpha chain;
DE   Contains:
DE     RecName: Full=Fibrinopeptide A;
DE   Contains:
DE     RecName: Full=Fibrinogen alpha chain;
DE   Flags: Precursor;
GN   Name=FGA;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND ALTERNATIVE SPLICING (ISOFORMS
RP   1 AND 2).
RX   PubMed=1457396; DOI=10.1021/bi00163a002;
RA   Fu Y., Weissbach L., Plant P.W., Oddoux C., Cao Y., Liang T.J.,
RA   Roy S.N., Redman C.M., Grieninger G.;
RT   "Carboxy-terminal-extended variant of the human fibrinogen alpha
RT   subunit: a novel exon conferring marked homology to beta and gamma
RT   subunits.";
RL   Biochemistry 31:11968-11972(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE (ISOFORM 1).
RA   Chung D.W., Grieninger G.;
RT   "Fibrinogen DNA and protein sequences.";
RL   (In) Ebert R.F. (eds.);
RL   Index of variant human fibrinogens, pp.13-24, CRC Press, Boca Raton
RL   (1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS VAL-6; ALA-331 AND
RP   ALA-456.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (JUN-2001) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT
RP   ALA-331.
RC   TISSUE=Heart;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE OF 1-655 (ISOFORM 1).
RC   TISSUE=Liver;
RX   PubMed=2102623;
RA   Chung D.W., Harris J.E., Davie E.W.;
RT   "Nucleotide sequences of the three genes coding for human
RT   fibrinogen.";
RL   Adv. Exp. Med. Biol. 281:39-48(1990).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=6575389; DOI=10.1073/pnas.80.13.3953;
RA   Kant J.A., Lord S.T., Crabtree G.R.;
RT   "Partial mRNA sequences for human A alpha, B beta, and gamma
RT   fibrinogen chains: evolutionary and functional implications.";
RL   Proc. Natl. Acad. Sci. U.S.A. 80:3953-3957(1983).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-629.
RX   PubMed=6688355; DOI=10.1021/bi00282a031;
RA   Rixon M.W., Chan W.-Y., Davie E.W., Chung D.W.;
RT   "Characterization of a complementary deoxyribonucleic acid coding for
RT   the alpha chain of human fibrinogen.";
RL   Biochemistry 22:3237-3244(1983).
RN   [10]
RP   PROTEIN SEQUENCE OF 20-629.
RA   Henschen A., Lottspeich F., Southan C., Topfer-Petersen E.;
RT   "Human fibrinogen: sequence, sulfur bridges, glycosylation and some
RT   structural variants.";
RL   (In) Peeters H. (eds.);
RL   Protides of the biological fluids, Proc. 28th colloquium, pp.51-56,
RL   Pergamon Press, Oxford (1980).
RN   [11]
RP   PROTEIN SEQUENCE OF 20-629, DISULFIDE BONDS, AND SUBUNIT.
RX   PubMed=518846; DOI=10.1021/bi00591a024;
RA   Watt K.W.K., Cottrell B.A., Strong D.D., Doolittle R.F.;
RT   "Amino acid sequence studies on the alpha chain of human fibrinogen.
RT   Overlapping sequences providing the complete sequence.";
RL   Biochemistry 18:5410-5416(1979).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 110-156.
RX   PubMed=6689067; DOI=10.1093/nar/11.21.7427;
RA   Imam A.M.A., Eaton M.A.W., Williamson R., Humphries S.;
RT   "Isolation and characterisation of cDNA clones for the A alpha- and
RT   gamma-chains of human fibrinogen.";
RL   Nucleic Acids Res. 11:7427-7434(1983).
RN   [13]
RP   NUCLEOTIDE SEQUENCE OF 605-644 (ISOFORM 2).
RX   PubMed=6575700; DOI=10.1111/j.1749-6632.1983.tb23265.x;
RA   Chung D.W., Rixon M.W., Que B.G., Davie E.W.;
RT   "Cloning of fibrinogen genes and their cDNA.";
RL   Ann. N. Y. Acad. Sci. 408:449-456(1983).
RN   [14]
RP   PROTEIN SEQUENCE OF 20-35.
RA   Blombaeck B., Blombaeck M., Grondahl N.J., Guthrie C., Hinton M.;
RT   "Studies on fibrinopeptides from primates.";
RL   Acta Chem. Scand. 19:1788-1789(1965).
RN   [15]
RP   DISULFIDE BONDS, AND SUBUNIT.
RX   PubMed=741445; DOI=10.1016/0049-3848(78)90142-1;
RA   Bouma H., Takagi T., Doolittle R.F.;
RT   "The arrangement of disulfide bonds in fragment D from human
RT   fibrinogen.";
RL   Thromb. Res. 13:557-562(1978).
RN   [16]
RP   CROSS-LINKING ACCEPTOR SITES.
RX   PubMed=518845; DOI=10.1021/bi00591a023;
RA   Cottrell B.A., Strong D.D., Watt K.W.K., Doolittle R.F.;
RT   "Amino acid sequence studies on the alpha chain of human fibrinogen.
RT   Exact location of cross-linking acceptor sites.";
RL   Biochemistry 18:5405-5410(1979).
RN   [17]
RP   CROSS-LINKING ACCEPTOR SITES.
RX   PubMed=632262;
RA   Fretto L.J., Ferguson E.W., Steinman H.M., McKee P.A.;
RT   "Localization of the alpha-chain cross-link acceptor sites of human
RT   fibrin.";
RL   J. Biol. Chem. 253:2184-2195(1978).
RN   [18]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-686.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [19]
RP   DISULFIDE BONDS, AND SUBUNIT.
RX   PubMed=936108; DOI=10.1016/0049-3848(76)90245-0;
RA   Blombaeck B., Hessel B., Hogg D.;
RT   "Disulfide bridges in NH2-terminal part of human fibrinogen.";
RL   Thromb. Res. 8:639-658(1976).
RN   [20]
RP   REVIEW, ELECTRON MICROSCOPY, POLYMERIZATION, AND LIGANDS.
RX   PubMed=6383194; DOI=10.1146/annurev.bi.53.070184.001211;
RA   Doolittle R.F.;
RT   "Fibrinogen and fibrin.";
RL   Annu. Rev. Biochem. 53:195-229(1984).
RN   [21]
RP   CROSS-LINKING SITE FOR ALPHA-2-PLASMIN INHIBITOR.
RX   PubMed=2877981;
RA   Kimura S., Aoki N.;
RT   "Cross-linking site in fibrinogen for alpha 2-plasmin inhibitor.";
RL   J. Biol. Chem. 261:15591-15595(1986).
RN   [22]
RP   PHOSPHORYLATION.
RX   PubMed=6318767; DOI=10.1016/0006-291X(83)91247-0;
RA   Itarte E., Plana M., Guasch M.D., Martos C.;
RT   "Phosphorylation of fibrinogen by casein kinase 1.";
RL   Biochem. Biophys. Res. Commun. 117:631-636(1983).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-22, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Pituitary;
RX   PubMed=16807684; DOI=10.1007/s11102-006-8916-x;
RA   Beranova-Giorgianni S., Zhao Y., Desiderio D.M., Giorgianni F.;
RT   "Phosphoproteomic analysis of the human pituitary.";
RL   Pituitary 9:109-120(2006).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-412 AND SER-609, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [25]
RP   HYDROXYLATION AT PRO-565.
RX   PubMed=19696023; DOI=10.1074/jbc.M109.041749;
RA   Ono M., Matsubara J., Honda K., Sakuma T., Hashiguchi T., Nose H.,
RA   Nakamori S., Okusaka T., Kosuge T., Sata N., Nagai H., Ioka T.,
RA   Tanaka S., Tsuchida A., Aoki T., Shimahara M., Yasunami Y., Itoi T.,
RA   Moriyasu F., Negishi A., Kuwabara H., Shoji A., Hirohashi S.,
RA   Yamada T.;
RT   "Prolyl 4-hydroxylation of alpha-fibrinogen: a novel protein
RT   modification revealed by plasma proteomics.";
RL   J. Biol. Chem. 284:29041-29049(2009).
RN   [26]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-686.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [27]
RP   CLEAVAGE BY HEMENTIN AND PLASMIN.
RX   PubMed=2143188;
RA   Kirschbaum N.E., Budzynski A.Z.;
RT   "A unique proteolytic fragment of human fibrinogen containing the A
RT   alpha COOH-terminal domain of the native molecule.";
RL   J. Biol. Chem. 265:13669-13676(1990).
RN   [28]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [29]
RP   GLYCOSYLATION AT THR-320 AND SER-351.
RX   PubMed=23050552; DOI=10.1021/pr3005937;
RA   Zauner G., Hoffmann M., Rapp E., Koeleman C.A., Dragan I.,
RA   Deelder A.M., Wuhrer M., Hensbergen P.J.;
RT   "Glycoproteomic analysis of human fibrinogen reveals novel regions of
RT   O-glycosylation.";
RL   J. Proteome Res. 11:5804-5814(2012).
RN   [30]
RP   LACK OF GLYCOSYLATION.
RX   PubMed=23151259; DOI=10.1021/pr300813h;
RA   Adamczyk B., Struwe W.B., Ercan A., Nigrovic P.A., Rudd P.M.;
RT   "Characterization of fibrinogen glycosylation and its importance for
RT   serum/plasma N-glycome analysis.";
RL   J. Proteome Res. 12:444-454(2013).
RN   [31]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-45; SER-50; SER-281;
RP   SER-291; SER-294; THR-412; SER-451; SER-501; THR-505 AND SER-609, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [32]
RP   PHOSPHORYLATION AT SER-45; SER-56; SER-364; SER-524; SER-560 AND
RP   SER-609.
RX   PubMed=26091039; DOI=10.1016/j.cell.2015.05.028;
RA   Tagliabracci V.S., Wiley S.E., Guo X., Kinch L.N., Durrant E., Wen J.,
RA   Xiao J., Cui J., Nguyen K.B., Engel J.L., Coon J.J., Grishin N.,
RA   Pinna L.A., Pagliarini D.J., Dixon J.E.;
RT   "A single kinase generates the majority of the secreted
RT   phosphoproteome.";
RL   Cell 161:1619-1632(2015).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 26-39.
RX   PubMed=1560020;
RA   Martin P.D., Robertson W., Turk D., Huber R., Bode W., Edwards B.F.P.;
RT   "The structure of residues 7-16 of the A alpha-chain of human
RT   fibrinogen bound to bovine thrombin at 2.3-A resolution.";
RL   J. Biol. Chem. 267:7911-7920(1992).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) OF 130-216, DISULFIDE BONDS,
RP   AND SUBUNIT.
RX   PubMed=9333233; DOI=10.1038/38947;
RA   Spraggon G., Everse S.J., Doolittle R.F.;
RT   "Crystal structures of fragment D from human fibrinogen and its
RT   crosslinked counterpart from fibrin.";
RL   Nature 389:455-462(1997).
RN   [35]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 130-216, SUBUNIT, DISULFIDE
RP   BONDS, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND COILED COIL
RP   DOMAIN.
RX   PubMed=9628725; DOI=10.1021/bi9804129;
RA   Everse S.J., Spraggon G., Veerapandian L., Riley M., Doolittle R.F.;
RT   "Crystal structure of fragment double-D from human fibrin with two
RT   different bound ligands.";
RL   Biochemistry 37:8637-8642(1998).
RN   [36]
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 666-866 IN COMPLEX WITH
RP   CALCIUM IONS, GLYCOSYLATION AT ASN-686, DISULFIDE BONDS, AND SUBUNIT.
RX   PubMed=9689040; DOI=10.1073/pnas.95.16.9099;
RA   Spraggon G., Applegate D., Everse S.J., Zhang J.Z., Veerapandian L.,
RA   Redman C., Doolittle R.F., Grieninger G.;
RT   "Crystal structure of a recombinant alphaEC domain from human
RT   fibrinogen-420.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:9099-9104(1998).
RN   [37]
RP   X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 130-216, AND DISULFIDE
RP   BONDS.
RX   PubMed=10074346; DOI=10.1021/bi982626w;
RA   Everse S.J., Spraggon G., Veerapandian L., Doolittle R.F.;
RT   "Conformational changes in fragments D and double-D from human
RT   fibrin(ogen) upon binding the peptide ligand Gly-His-Arg-Pro-amide.";
RL   Biochemistry 38:2941-2946(1999).
RN   [38]
RP   X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) OF 20-581, SUBUNIT, DISULFIDE
RP   BONDS, COILED COIL DOMAIN, SUBCELLULAR LOCATION, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=19296670; DOI=10.1021/bi802205g;
RA   Kollman J.M., Pandi L., Sawaya M.R., Riley M., Doolittle R.F.;
RT   "Crystal structure of human fibrinogen.";
RL   Biochemistry 48:3877-3886(2009).
RN   [39]
RP   VARIANT KYOTO-2 LEU-37.
RX   PubMed=2070049;
RA   Yoshida N., Okuma M., Hirata H., Matsuda M., Yamazumi K., Asakura S.;
RT   "Fibrinogen Kyoto II, a new congenitally abnormal molecule,
RT   characterized by the replacement of A alpha proline-18 by leucine.";
RL   Blood 78:149-153(1991).
RN   [40]
RP   VARIANT LIMA SER-160.
RX   PubMed=1634621; DOI=10.1172/JCI115857;
RA   Maekawa H., Yamazumi K., Muramatsu S., Kaneko M., Hirata H.,
RA   Takahashi N., Arocha-Pinango C.L., Rodriguez S., Nagy H.,
RA   Perez-Requejo J.L., Matsuda M.;
RT   "Fibrinogen Lima: a homozygous dysfibrinogen with an A alpha-arginine-
RT   141 to serine substitution associated with extra N-glycosylation at A
RT   alpha-asparagine-139. Impaired fibrin gel formation but normal fibrin-
RT   facilitated plasminogen activation catalyzed by tissue-type
RT   plasminogen activator.";
RL   J. Clin. Invest. 90:67-76(1992).
RN   [41]
RP   VARIANT CARACAS-2 ASN-453.
RX   PubMed=1675636;
RA   Maekawa H., Yamazumi K., Muramatsu S., Kaneko M., Hirata H.,
RA   Takahashi N., de Bosch N.B., Carvajal Z., Ojeda A.,
RA   Arocha-Pinango C.L., Matsuda M.;
RT   "An A alpha Ser-434 to N-glycosylated Asn substitution in a
RT   dysfibrinogen, fibrinogen Caracas II, characterized by impaired fibrin
RT   gel formation.";
RL   J. Biol. Chem. 266:11575-11581(1991).
RN   [42]
RP   INVOLVEMENT IN DYSFIBRIN, AND VARIANT DYSFIBRIN CYS-573.
RX   PubMed=8473507; DOI=10.1172/JCI116371;
RA   Koopman J., Haverkate F., Grimbergen J., Lord S.T., Mosesson M.W.,
RA   Diorio J.P., Siebenlist K.S., Legrand C., Soria J., Soria C.,
RA   Caen J.P.;
RT   "Molecular basis for fibrinogen Dusart (A alpha 554 Arg-->Cys) and its
RT   association with abnormal fibrin polymerization and thrombophilia.";
RL   J. Clin. Invest. 91:1637-1643(1993).
RN   [43]
RP   VARIANT AMYL8 LEU-573.
RX   PubMed=8097946; DOI=10.1038/ng0393-252;
RA   Benson M.D., Liepnieks J., Uemichi T., Wheeler G., Correa R.;
RT   "Hereditary renal amyloidosis associated with a mutant fibrinogen
RT   alpha-chain.";
RL   Nat. Genet. 3:252-255(1993).
RN   [44]
RP   VARIANT OSAKA IV HIS-35.
RX   PubMed=8461606; DOI=10.1007/BF00308999;
RA   Yamazumi K., Terukina S., Matsuda M., Kanbayashi J., Sakon M.,
RA   Tsujinaka T.;
RT   "Fibrinogen Osaka IV: a congenital dysfibrinogenemia found in a
RT   patient originally reported in relation to surgery, now defined to
RT   have an A alpha arginine-16 to histidine substitution.";
RL   Surg. Today 23:45-50(1993).
RN   [45]
RP   VARIANT CANTERBURY ASP-39.
RX   PubMed=8675656; DOI=10.1172/JCI118356;
RA   Brennan S.O., Hammonds B., George P.M.;
RT   "Aberrant hepatic processing causes removal of activation peptide and
RT   primary polymerisation site from fibrinogen Canterbury (A-alpha 20
RT   Val-to-Asp).";
RL   J. Clin. Invest. 96:2854-2858(1995).
RN   [46]
RP   VARIANTS ALA-331 AND GLU-446.
RX   PubMed=10391209; DOI=10.1038/10290;
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RT   "Characterization of single-nucleotide polymorphisms in coding regions
RT   of human genes.";
RL   Nat. Genet. 22:231-238(1999).
RN   [47]
RP   ERRATUM.
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RL   Nat. Genet. 23:373-373(1999).
RN   [48]
RP   INVOLVEMENT IN DYSFIBRIN, AND VARIANT DYSFIBRIN CYS-35.
RX   PubMed=16846481; DOI=10.1111/j.1365-2141.2006.06129.x;
RA   Flood V.H., Al-Mondhiry H.A., Farrell D.H.;
RT   "The fibrinogen Aalpha R16C mutation results in fibrinolytic
RT   resistance.";
RL   Br. J. Haematol. 134:220-226(2006).
RN   [49]
RP   INVOLVEMENT IN CAFBN; VARIANTS CAFBN ARG-55; PRO-129 AND TRP-184, AND
RP   CHARACTERIZATION OF VARIANTS CAFBN ARG-55; PRO-129 AND TRP-184.
RX   PubMed=25427968; DOI=10.1160/TH14-07-0629;
RA   Asselta R., Plate M., Robusto M., Borhany M., Guella I., Solda G.,
RA   Afrasiabi A., Menegatti M., Shamsi T., Peyvandi F., Duga S.;
RT   "Clinical and molecular characterisation of 21 patients affected by
RT   quantitative fibrinogen deficiency.";
RL   Thromb. Haemost. 113:567-576(2015).
CC   -!- FUNCTION: Cleaved by the protease thrombin to yield monomers
CC       which, together with fibrinogen beta (FGB) and fibrinogen gamma
CC       (FGG), polymerize to form an insoluble fibrin matrix. Fibrin has a
CC       major function in hemostasis as one of the primary components of
CC       blood clots. In addition, functions during the early stages of
CC       wound repair to stabilize the lesion and guide cell migration
CC       during re-epithelialization. Was originally thought to be
CC       essential for platelet aggregation, based on in vitro studies
CC       using anticoagulated blood. However, subsequent studies have shown
CC       that it is not absolutely required for thrombus formation in vivo.
CC       Enhances expression of SELP in activated platelets via an ITGB3-
CC       dependent pathway. Maternal fibrinogen is essential for successful
CC       pregnancy. Fibrin deposition is also associated with infection,
CC       where it protects against IFNG-mediated hemorrhage. May also
CC       facilitate the immune response via both innate and T-cell mediated
CC       pathways. {ECO:0000250|UniProtKB:E9PV24}.
CC   -!- SUBUNIT: Heterohexamer; disulfide linked. Contains 2 sets of 3
CC       non-identical chains (alpha, beta and gamma). The 2 heterotrimers
CC       are in head to head conformation with the N-termini in a small
CC       central domain. {ECO:0000269|PubMed:518846,
CC       ECO:0000269|PubMed:741445, ECO:0000269|PubMed:9333233,
CC       ECO:0000269|PubMed:936108, ECO:0000269|PubMed:9628725,
CC       ECO:0000269|PubMed:9689040}.
CC   -!- INTERACTION:
CC       P02647:APOA1; NbExp=2; IntAct=EBI-348571, EBI-701692;
CC       Q8IXL6:FAM20C; NbExp=2; IntAct=EBI-348571, EBI-7147442;
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:19296670,
CC       ECO:0000269|PubMed:9628725}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=Alpha-E;
CC         IsoId=P02671-1; Sequence=Displayed;
CC       Name=2; Synonyms=Alpha;
CC         IsoId=P02671-2; Sequence=VSP_001531, VSP_001532;
CC         Note=Ref.3 (AAK31372) sequence is in conflict in positions:
CC         640:PSLSP->LPCPPRLS. {ECO:0000305};
CC   -!- TISSUE SPECIFICITY: Detected in blood plasma (at protein level).
CC       {ECO:0000269|PubMed:19296670, ECO:0000269|PubMed:9628725}.
CC   -!- DOMAIN: A long coiled coil structure formed by 3 polypeptide
CC       chains connects the central nodule to the C-terminal domains
CC       (distal nodules). The long C-terminal ends of the alpha chains
CC       fold back, contributing a fourth strand to the coiled coil
CC       structure. {ECO:0000269|PubMed:19296670,
CC       ECO:0000269|PubMed:9628725, ECO:0000305}.
CC   -!- PTM: The alpha chain is normally not N-glycosylated
CC       (PubMed:23151259), even though glycosylation at Asn-686 was
CC       observed when a fragment of the protein was expressed in insect
CC       cells (PubMed:9689040). It is well known that heterologous
CC       expression of isolated domains can lead to adventitious protein
CC       modifications. Besides, glycosylation at Asn-686 is supported by
CC       large-scale glycoproteomics studies (PubMed:16335952 and
CC       PubMed:19159218), but the evidence is still quite tenuous. Most
CC       likely, Asn-686 is not glycosylated in the healthy human body, or
CC       only with low efficiency. {ECO:0000269|PubMed:16335952,
CC       ECO:0000269|PubMed:19159218, ECO:0000269|PubMed:23151259,
CC       ECO:0000269|PubMed:9689040, ECO:0000305}.
CC   -!- PTM: O-glycosylated. {ECO:0000269|PubMed:23050552}.
CC   -!- PTM: Forms F13A-mediated cross-links between a glutamine and the
CC       epsilon-amino group of a lysine residue, forming fibronectin-
CC       fibrinogen heteropolymers.
CC   -!- PTM: About one-third of the alpha chains in the molecules in blood
CC       were found to be phosphorylated.
CC   -!- PTM: Conversion of fibrinogen to fibrin is triggered by thrombin,
CC       which cleaves fibrinopeptides A and B from alpha and beta chains,
CC       and thus exposes the N-terminal polymerization sites responsible
CC       for the formation of the soft clot. The soft clot is converted
CC       into the hard clot by factor XIIIA which catalyzes the epsilon-
CC       (gamma-glutamyl)lysine cross-linking between gamma chains
CC       (stronger) and between alpha chains (weaker) of different
CC       monomers. {ECO:0000269|PubMed:2143188}.
CC   -!- PTM: Phosphorylated by FAM20C in the extracellular medium.
CC       {ECO:0000269|PubMed:26091039}.
CC   -!- DISEASE: Congenital afibrinogenemia (CAFBN) [MIM:202400]: Rare
CC       autosomal recessive disorder is characterized by bleeding that
CC       varies from mild to severe and by complete absence or extremely
CC       low levels of plasma and platelet fibrinogen.
CC       {ECO:0000269|PubMed:25427968}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry. The
CC       majority of cases of afibrinogenemia are due to truncating
CC       mutations. Variations in position Arg-35 (the site of cleavage of
CC       fibrinopeptide a by thrombin) leads to alpha-dysfibrinogenemias.
CC   -!- DISEASE: Amyloidosis 8 (AMYL8) [MIM:105200]: A form of hereditary
CC       generalized amyloidosis. Clinical features include extensive
CC       visceral amyloid deposits, renal amyloidosis resulting in
CC       nephrotic syndrome, arterial hypertension, hepatosplenomegaly,
CC       cholestasis, petechial skin rash. There is no involvement of the
CC       nervous system. {ECO:0000269|PubMed:8097946}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Dysfibrinogenemia, congenital (DYSFIBRIN) [MIM:616004]: A
CC       disorder characterized by qualitative abnormalities
CC       (dysfibrinogenemia) of the circulating fibrinogen. Affected
CC       individuals are frequently asymptomatic, but some patients have
CC       bleeding diathesis, thromboembolic complications, or both. In some
CC       cases, dysfibrinogenemia is associated with low circulating
CC       fibrinogen levels (hypodysfibrinogenemia).
CC       {ECO:0000269|PubMed:16846481, ECO:0000269|PubMed:8473507}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation and
CC       polymorphism database;
CC       URL="http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=FGA";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Fibrinogen entry;
CC       URL="https://en.wikipedia.org/wiki/Fibrinogen";
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/fga/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M64982; AAA17056.1; -; Genomic_DNA.
DR   EMBL; M64982; AAA17055.1; -; Genomic_DNA.
DR   EMBL; M58569; AAC97142.1; -; Transcribed_RNA.
DR   EMBL; M58569; AAC97143.1; -; Transcribed_RNA.
DR   EMBL; AF361104; AAK31372.1; -; Genomic_DNA.
DR   EMBL; AF361104; AAK31373.1; -; Genomic_DNA.
DR   EMBL; AK290559; BAF83248.1; -; mRNA.
DR   EMBL; CH471056; EAX04925.1; -; Genomic_DNA.
DR   EMBL; CH471056; EAX04926.1; -; Genomic_DNA.
DR   EMBL; CH471056; EAX04927.1; -; Genomic_DNA.
DR   EMBL; CH471056; EAX04928.1; -; Genomic_DNA.
DR   EMBL; BC098280; AAH98280.1; -; mRNA.
DR   EMBL; BC099706; AAH99706.1; -; mRNA.
DR   EMBL; BC099720; AAH99720.1; -; mRNA.
DR   EMBL; BC101935; AAI01936.1; -; mRNA.
DR   EMBL; J00128; AAA52427.1; -; mRNA.
DR   EMBL; J00127; AAA52426.1; -; mRNA.
DR   EMBL; K02272; AAA52428.1; -; mRNA.
DR   EMBL; M26878; AAA52444.1; -; mRNA.
DR   CCDS; CCDS3787.1; -. [P02671-1]
DR   CCDS; CCDS47152.1; -. [P02671-2]
DR   PIR; A93956; FGHUA.
DR   PIR; D44234; D44234.
DR   RefSeq; NP_000499.1; NM_000508.4. [P02671-1]
DR   RefSeq; NP_068657.1; NM_021871.3. [P02671-2]
DR   UniGene; Hs.351593; -.
DR   UniGene; Hs.612036; -.
DR   PDB; 1BBR; X-ray; 2.30 A; F/G/I=26-35.
DR   PDB; 1DM4; X-ray; 2.50 A; C=26-35.
DR   PDB; 1FPH; X-ray; 2.50 A; F=26-35.
DR   PDB; 1FZA; X-ray; 2.90 A; A/D=130-216.
DR   PDB; 1FZB; X-ray; 2.90 A; A/D=130-216.
DR   PDB; 1FZC; X-ray; 2.30 A; A/D=130-216.
DR   PDB; 1FZD; X-ray; 2.10 A; A/B/C/D/E/F/G/H=666-866.
DR   PDB; 1FZE; X-ray; 3.00 A; A/D=130-216.
DR   PDB; 1FZF; X-ray; 2.70 A; A/D=130-216.
DR   PDB; 1FZG; X-ray; 2.50 A; A/D=130-216.
DR   PDB; 1LT9; X-ray; 2.80 A; A/D=145-210.
DR   PDB; 1LTJ; X-ray; 2.80 A; A/D=145-210.
DR   PDB; 1N86; X-ray; 3.20 A; A/D=130-216.
DR   PDB; 1N8E; X-ray; 4.50 A; A/D=130-218.
DR   PDB; 1RE3; X-ray; 2.45 A; A/D=145-210.
DR   PDB; 1RE4; X-ray; 2.70 A; A/D=145-210.
DR   PDB; 1RF0; X-ray; 2.81 A; A/D=145-210.
DR   PDB; 1RF1; X-ray; 2.53 A; A/D=145-210.
DR   PDB; 1YCP; X-ray; 2.50 A; F/N=20-42.
DR   PDB; 2A45; X-ray; 3.65 A; G/J=36-92.
DR   PDB; 2FFD; X-ray; 2.89 A; A/D=145-210.
DR   PDB; 2H43; X-ray; 2.70 A; A/D=130-216.
DR   PDB; 2HLO; X-ray; 2.60 A; A/D=130-216.
DR   PDB; 2HOD; X-ray; 2.90 A; A/D/G/J=130-216.
DR   PDB; 2HPC; X-ray; 2.90 A; A/D/G/J=130-216.
DR   PDB; 2OYH; X-ray; 2.40 A; A/D=145-210.
DR   PDB; 2OYI; X-ray; 2.70 A; A/D=145-210.
DR   PDB; 2Q9I; X-ray; 2.80 A; A/D=130-216.
DR   PDB; 2XNX; X-ray; 3.30 A; A/D/G/J=130-216.
DR   PDB; 2XNY; X-ray; 7.50 A; A/D=130-216.
DR   PDB; 2Z4E; X-ray; 2.70 A; A/D=130-216.
DR   PDB; 3AT0; X-ray; 2.50 A; B=332-347.
DR   PDB; 3BVH; X-ray; 2.60 A; A/D=148-209.
DR   PDB; 3E1I; X-ray; 2.30 A; A/D=130-216.
DR   PDB; 3GHG; X-ray; 2.90 A; A/D/G/J=20-581.
DR   PDB; 3H32; X-ray; 3.60 A; A/D=20-216.
DR   PDB; 3HUS; X-ray; 3.04 A; A/D=145-210.
DR   PDB; 4F27; X-ray; 1.92 A; Q=336-347.
DR   PDB; 5CFA; X-ray; 1.45 A; C/D=580-594.
DR   PDBsum; 1BBR; -.
DR   PDBsum; 1DM4; -.
DR   PDBsum; 1FPH; -.
DR   PDBsum; 1FZA; -.
DR   PDBsum; 1FZB; -.
DR   PDBsum; 1FZC; -.
DR   PDBsum; 1FZD; -.
DR   PDBsum; 1FZE; -.
DR   PDBsum; 1FZF; -.
DR   PDBsum; 1FZG; -.
DR   PDBsum; 1LT9; -.
DR   PDBsum; 1LTJ; -.
DR   PDBsum; 1N86; -.
DR   PDBsum; 1N8E; -.
DR   PDBsum; 1RE3; -.
DR   PDBsum; 1RE4; -.
DR   PDBsum; 1RF0; -.
DR   PDBsum; 1RF1; -.
DR   PDBsum; 1YCP; -.
DR   PDBsum; 2A45; -.
DR   PDBsum; 2FFD; -.
DR   PDBsum; 2H43; -.
DR   PDBsum; 2HLO; -.
DR   PDBsum; 2HOD; -.
DR   PDBsum; 2HPC; -.
DR   PDBsum; 2OYH; -.
DR   PDBsum; 2OYI; -.
DR   PDBsum; 2Q9I; -.
DR   PDBsum; 2XNX; -.
DR   PDBsum; 2XNY; -.
DR   PDBsum; 2Z4E; -.
DR   PDBsum; 3AT0; -.
DR   PDBsum; 3BVH; -.
DR   PDBsum; 3E1I; -.
DR   PDBsum; 3GHG; -.
DR   PDBsum; 3H32; -.
DR   PDBsum; 3HUS; -.
DR   PDBsum; 4F27; -.
DR   PDBsum; 5CFA; -.
DR   ProteinModelPortal; P02671; -.
DR   SMR; P02671; -.
DR   BioGrid; 108534; 27.
DR   DIP; DIP-29643N; -.
DR   IntAct; P02671; 18.
DR   MINT; MINT-1033042; -.
DR   STRING; 9606.ENSP00000306361; -.
DR   ChEMBL; CHEMBL2364709; -.
DR   DrugBank; DB04919; Alfimeprase.
DR   DrugBank; DB00009; Alteplase.
DR   DrugBank; DB05099; Ancrod.
DR   DrugBank; DB00029; Anistreplase.
DR   DrugBank; DB05675; EP-2104R.
DR   DrugBank; DB00015; Reteplase.
DR   DrugBank; DB00364; Sucralfate.
DR   DrugBank; DB00031; Tenecteplase.
DR   iPTMnet; P02671; -.
DR   PhosphoSitePlus; P02671; -.
DR   SwissPalm; P02671; -.
DR   UniCarbKB; P02671; -.
DR   BioMuta; FGA; -.
DR   DMDM; 1706799; -.
DR   OGP; P02671; -.
DR   SWISS-2DPAGE; P02671; -.
DR   MaxQB; P02671; -.
DR   PaxDb; P02671; -.
DR   PeptideAtlas; P02671; -.
DR   PRIDE; P02671; -.
DR   DNASU; 2243; -.
DR   Ensembl; ENST00000302053; ENSP00000306361; ENSG00000171560. [P02671-1]
DR   Ensembl; ENST00000403106; ENSP00000385981; ENSG00000171560. [P02671-2]
DR   GeneID; 2243; -.
DR   KEGG; hsa:2243; -.
DR   UCSC; uc003iod.2; human. [P02671-1]
DR   CTD; 2243; -.
DR   DisGeNET; 2243; -.
DR   GeneCards; FGA; -.
DR   HGNC; HGNC:3661; FGA.
DR   HPA; CAB016776; -.
DR   HPA; HPA051370; -.
DR   HPA; HPA064755; -.
DR   MalaCards; FGA; -.
DR   MIM; 105200; phenotype.
DR   MIM; 134820; gene+phenotype.
DR   MIM; 202400; phenotype.
DR   MIM; 616004; phenotype.
DR   neXtProt; NX_P02671; -.
DR   OpenTargets; ENSG00000171560; -.
DR   Orphanet; 98880; Familial afibrinogenemia.
DR   Orphanet; 98881; Familial dysfibrinogenemia.
DR   Orphanet; 248408; Familial hypodysfibrinogenemia.
DR   Orphanet; 101041; Familial hypofibrinogenemia.
DR   Orphanet; 93562; Familial renal amyloidosis due to fibrinogen A alpha-chain variant.
DR   PharmGKB; PA429; -.
DR   eggNOG; KOG2579; Eukaryota.
DR   eggNOG; ENOG410ZYS4; LUCA.
DR   GeneTree; ENSGT00830000128240; -.
DR   HOGENOM; HOG000285947; -.
DR   HOVERGEN; HBG005668; -.
DR   InParanoid; P02671; -.
DR   KO; K03903; -.
DR   OMA; PGSTGTW; -.
DR   OrthoDB; EOG091G03M1; -.
DR   PhylomeDB; P02671; -.
DR   TreeFam; TF351984; -.
DR   Reactome; R-HSA-114608; Platelet degranulation.
DR   Reactome; R-HSA-140875; Common Pathway of Fibrin Clot Formation.
DR   Reactome; R-HSA-216083; Integrin cell surface interactions.
DR   Reactome; R-HSA-354192; Integrin alphaIIb beta3 signaling.
DR   Reactome; R-HSA-354194; GRB2:SOS provides linkage to MAPK signaling for Integrins.
DR   Reactome; R-HSA-372708; p130Cas linkage to MAPK signaling for integrins.
DR   Reactome; R-HSA-5674135; MAP2K and MAPK activation.
DR   Reactome; R-HSA-5686938; Regulation of TLR by endogenous ligand.
DR   Reactome; R-HSA-6802946; Signaling by moderate kinase activity BRAF mutants.
DR   Reactome; R-HSA-6802948; Signaling by high-kinase activity BRAF mutants.
DR   Reactome; R-HSA-6802949; Signaling by RAS mutants.
DR   Reactome; R-HSA-6802952; Signaling by BRAF and RAF fusions.
DR   Reactome; R-HSA-6802955; Paradoxical activation of RAF signaling by kinase inactive BRAF.
DR   Reactome; R-HSA-977225; Amyloid fiber formation.
DR   SIGNOR; P02671; -.
DR   ChiTaRS; FGA; human.
DR   EvolutionaryTrace; P02671; -.
DR   GeneWiki; Fibrinogen_alpha_chain; -.
DR   GenomeRNAi; 2243; -.
DR   PMAP-CutDB; P02671; -.
DR   PRO; PR:P02671; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   Bgee; ENSG00000171560; -.
DR   CleanEx; HS_FGA; -.
DR   ExpressionAtlas; P02671; baseline and differential.
DR   Genevisible; P02671; HS.
DR   GO; GO:0072562; C:blood microparticle; IDA:UniProtKB.
DR   GO; GO:0005938; C:cell cortex; IEA:Ensembl.
DR   GO; GO:0009986; C:cell surface; IDA:BHF-UCL.
DR   GO; GO:0009897; C:external side of plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:BHF-UCL.
DR   GO; GO:1903561; C:extracellular vesicle; IDA:UniProtKB.
DR   GO; GO:0005577; C:fibrinogen complex; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0031091; C:platelet alpha granule; IDA:BHF-UCL.
DR   GO; GO:0031093; C:platelet alpha granule lumen; TAS:Reactome.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0030674; F:protein binding, bridging; IEA:InterPro.
DR   GO; GO:0005102; F:receptor binding; IEA:InterPro.
DR   GO; GO:0005198; F:structural molecule activity; IDA:BHF-UCL.
DR   GO; GO:0002250; P:adaptive immune response; IEA:UniProtKB-KW.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0072377; P:blood coagulation, common pathway; IMP:BHF-UCL.
DR   GO; GO:0072378; P:blood coagulation, fibrin clot formation; IDA:UniProtKB.
DR   GO; GO:0007160; P:cell-matrix adhesion; IDA:BHF-UCL.
DR   GO; GO:0043623; P:cellular protein complex assembly; IDA:BHF-UCL.
DR   GO; GO:0044267; P:cellular protein metabolic process; TAS:Reactome.
DR   GO; GO:0030198; P:extracellular matrix organization; TAS:Reactome.
DR   GO; GO:0042730; P:fibrinolysis; IDA:UniProtKB.
DR   GO; GO:0043152; P:induction of bacterial agglutination; IDA:CACAO.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:2000261; P:negative regulation of blood coagulation, common pathway; TAS:BHF-UCL.
DR   GO; GO:2000352; P:negative regulation of endothelial cell apoptotic process; IDA:BHF-UCL.
DR   GO; GO:1902042; P:negative regulation of extrinsic apoptotic signaling pathway via death domain receptors; IDA:BHF-UCL.
DR   GO; GO:0031639; P:plasminogen activation; IDA:UniProtKB.
DR   GO; GO:0070527; P:platelet aggregation; IDA:BHF-UCL.
DR   GO; GO:0002576; P:platelet degranulation; TAS:Reactome.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:BHF-UCL.
DR   GO; GO:0045921; P:positive regulation of exocytosis; IDA:BHF-UCL.
DR   GO; GO:0034116; P:positive regulation of heterotypic cell-cell adhesion; IDA:BHF-UCL.
DR   GO; GO:0090277; P:positive regulation of peptide hormone secretion; IDA:BHF-UCL.
DR   GO; GO:0050714; P:positive regulation of protein secretion; IDA:BHF-UCL.
DR   GO; GO:1900026; P:positive regulation of substrate adhesion-dependent cell spreading; NAS:BHF-UCL.
DR   GO; GO:0045907; P:positive regulation of vasoconstriction; IDA:BHF-UCL.
DR   GO; GO:0006461; P:protein complex assembly; IMP:UniProtKB.
DR   GO; GO:0051258; P:protein polymerization; IDA:BHF-UCL.
DR   GO; GO:0051592; P:response to calcium ion; IDA:BHF-UCL.
DR   GO; GO:0002224; P:toll-like receptor signaling pathway; TAS:Reactome.
DR   CDD; cd00087; FReD; 1.
DR   Gene3D; 3.90.215.10; -; 1.
DR   Gene3D; 4.10.530.10; -; 1.
DR   InterPro; IPR014716; Fibrinogen_a/b/g_C_1.
DR   InterPro; IPR014715; Fibrinogen_a/b/g_C_2.
DR   InterPro; IPR002181; Fibrinogen_a/b/g_C_dom.
DR   InterPro; IPR012290; Fibrinogen_a/b/g_coil_dom.
DR   InterPro; IPR021996; Fibrinogen_aC.
DR   InterPro; IPR020837; Fibrinogen_CS.
DR   Pfam; PF08702; Fib_alpha; 1.
DR   Pfam; PF12160; Fibrinogen_aC; 1.
DR   Pfam; PF00147; Fibrinogen_C; 1.
DR   SMART; SM00186; FBG; 1.
DR   SMART; SM01212; Fib_alpha; 1.
DR   SUPFAM; SSF56496; SSF56496; 1.
DR   PROSITE; PS00514; FIBRINOGEN_C_1; 1.
DR   PROSITE; PS51406; FIBRINOGEN_C_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Adaptive immunity; Alternative splicing; Amyloid;
KW   Amyloidosis; Blood coagulation; Calcium; Coiled coil;
KW   Complete proteome; Direct protein sequencing; Disease mutation;
KW   Disulfide bond; Glycoprotein; Hemostasis; Hydroxylation; Immunity;
KW   Innate immunity; Isopeptide bond; Metal-binding; Phosphoprotein;
KW   Polymorphism; Reference proteome; Secreted; Signal.
FT   SIGNAL        1     19       {ECO:0000269|PubMed:518846,
FT                                ECO:0000269|Ref.10, ECO:0000269|Ref.14}.
FT   PEPTIDE      20     35       Fibrinopeptide A.
FT                                /FTId=PRO_0000009021.
FT   CHAIN        36    866       Fibrinogen alpha chain.
FT                                /FTId=PRO_0000009022.
FT   DOMAIN      623    864       Fibrinogen C-terminal.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00739}.
FT   REGION       36     38       Alpha-chain polymerization, binding
FT                                distal domain of another fibrin gamma
FT                                chain.
FT   COILED       68    631       {ECO:0000305|PubMed:19296670}.
FT   METAL       791    791       Calcium. {ECO:0000244|PDB:1FZD,
FT                                ECO:0000269|PubMed:9689040}.
FT   METAL       793    793       Calcium. {ECO:0000244|PDB:1FZD,
FT                                ECO:0000269|PubMed:9689040}.
FT   METAL       795    795       Calcium; via carbonyl oxygen.
FT                                {ECO:0000244|PDB:1FZD,
FT                                ECO:0000269|PubMed:9689040}.
FT   METAL       797    797       Calcium; via carbonyl oxygen.
FT                                {ECO:0000244|PDB:1FZD,
FT                                ECO:0000269|PubMed:9689040}.
FT   SITE         35     36       Cleavage; by thrombin; to release
FT                                fibrinopeptide A.
FT   SITE        100    101       Cleavage; by plasmin; to break down
FT                                fibrin clots.
FT   SITE        121    122       Cleavage; by hementin; to prevent blood
FT                                coagulation.
FT   SITE        123    124       Cleavage; by plasmin; to break down
FT                                fibrin clots.
FT   MOD_RES      22     22       Phosphoserine.
FT                                {ECO:0000244|PubMed:16807684}.
FT   MOD_RES      45     45       Phosphoserine; by FAM20C.
FT                                {ECO:0000244|PubMed:24275569,
FT                                ECO:0000269|PubMed:26091039}.
FT   MOD_RES      50     50       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES      56     56       Phosphoserine; by FAM20C.
FT                                {ECO:0000269|PubMed:26091039}.
FT   MOD_RES     281    281       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     291    291       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     294    294       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     364    364       Phosphoserine; by FAM20C.
FT                                {ECO:0000269|PubMed:26091039}.
FT   MOD_RES     412    412       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18088087,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     451    451       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     501    501       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     505    505       Phosphothreonine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     524    524       Phosphoserine; by FAM20C.
FT                                {ECO:0000269|PubMed:26091039}.
FT   MOD_RES     560    560       Phosphoserine; by FAM20C.
FT                                {ECO:0000269|PubMed:26091039}.
FT   MOD_RES     565    565       4-hydroxyproline; by P4HA1.
FT                                {ECO:0000269|PubMed:19696023}.
FT   MOD_RES     609    609       Phosphoserine; by FAM20C.
FT                                {ECO:0000244|PubMed:18088087,
FT                                ECO:0000244|PubMed:24275569,
FT                                ECO:0000269|PubMed:26091039}.
FT   CARBOHYD    320    320       O-linked (GalNAc...) threonine.
FT                                {ECO:0000269|PubMed:23050552}.
FT   CARBOHYD    351    351       O-linked (GalNAc...) serine.
FT                                {ECO:0000269|PubMed:23050552}.
FT   CARBOHYD    453    453       N-linked (GlcNAc...) asparagine; in
FT                                variant Caracas-2.
FT   CARBOHYD    686    686       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:9689040}.
FT   DISULFID     47     47       Interchain.
FT                                {ECO:0000269|PubMed:19296670}.
FT   DISULFID     55     55       Interchain (with C-95 in beta chain).
FT                                {ECO:0000269|PubMed:19296670}.
FT   DISULFID     64     64       Interchain (with C-49 in gamma chain).
FT                                {ECO:0000269|PubMed:19296670}.
FT   DISULFID     68     68       Interchain (with C-106 in beta chain).
FT                                {ECO:0000269|PubMed:19296670}.
FT   DISULFID    180    180       Interchain (with C-165 in gamma chain).
FT                                {ECO:0000269|PubMed:19296670,
FT                                ECO:0000269|PubMed:741445,
FT                                ECO:0000269|PubMed:9333233,
FT                                ECO:0000269|PubMed:9628725}.
FT   DISULFID    184    184       Interchain (with C-223 in beta chain).
FT                                {ECO:0000269|PubMed:19296670,
FT                                ECO:0000269|PubMed:741445,
FT                                ECO:0000269|PubMed:9333233,
FT                                ECO:0000269|PubMed:9628725}.
FT   DISULFID    461    491       {ECO:0000250|UniProtKB:P02672}.
FT   DISULFID    799    812       {ECO:0000244|PDB:1FZD,
FT                                ECO:0000269|PubMed:9689040}.
FT   CROSSLNK    322    322       Isoglutamyl lysine isopeptide (Lys-Gln)
FT                                (interchain with Q-41 in alpha-2-
FT                                antiplasmin).
FT   CROSSLNK    347    347       Isoglutamyl lysine isopeptide (Gln-Lys)
FT                                (interchain with K-?).
FT   CROSSLNK    385    385       Isoglutamyl lysine isopeptide (Gln-Lys)
FT                                (interchain with K-?).
FT   CROSSLNK    527    527       Isoglutamyl lysine isopeptide (Lys-Gln)
FT                                (interchain with Q-?). {ECO:0000255}.
FT   CROSSLNK    558    558       Isoglutamyl lysine isopeptide (Lys-Gln)
FT                                (interchain with Q-?). {ECO:0000255}.
FT   CROSSLNK    575    575       Isoglutamyl lysine isopeptide (Lys-Gln)
FT                                (interchain with Q-?). {ECO:0000255}.
FT   CROSSLNK    581    581       Isoglutamyl lysine isopeptide (Lys-Gln)
FT                                (interchain with Q-?). {ECO:0000255}.
FT   CROSSLNK    599    599       Isoglutamyl lysine isopeptide (Lys-Gln)
FT                                (interchain with Q-?). {ECO:0000255}.
FT   VAR_SEQ     631    644       DCDDVLQTHPSGTQ -> GIHTSPLGKPSLSP (in
FT                                isoform 2). {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:6575389}.
FT                                /FTId=VSP_001531.
FT   VAR_SEQ     645    866       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:6575389}.
FT                                /FTId=VSP_001532.
FT   VARIANT       6      6       I -> V (in dbSNP:rs2070025).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_011609.
FT   VARIANT      26     26       D -> N (in Lille-1; dbSNP:rs121909604).
FT                                /FTId=VAR_002390.
FT   VARIANT      31     31       G -> V (in Rouen-1; dbSNP:rs121909605).
FT                                /FTId=VAR_002391.
FT   VARIANT      35     35       R -> C (in DYSFIBRIN; fibrinogen Metz 1/
FT                                Hershey III; dbSNP:rs121909606).
FT                                {ECO:0000269|PubMed:16846481}.
FT                                /FTId=VAR_002392.
FT   VARIANT      35     35       R -> H (in dbSNP:rs121909607).
FT                                {ECO:0000269|PubMed:8461606}.
FT                                /FTId=VAR_002393.
FT   VARIANT      37     37       P -> L (in Kyoto-2; dbSNP:rs121909609).
FT                                {ECO:0000269|PubMed:2070049}.
FT                                /FTId=VAR_002394.
FT   VARIANT      38     38       R -> G (in Aarhus-1; dbSNP:rs121909608).
FT                                /FTId=VAR_002397.
FT   VARIANT      38     38       R -> N (in Munich-1; requires 2
FT                                nucleotide substitutions).
FT                                /FTId=VAR_002395.
FT   VARIANT      38     38       R -> S (in Detroit-1).
FT                                /FTId=VAR_002396.
FT   VARIANT      39     39       V -> D (in Canterbury;
FT                                dbSNP:rs121909614).
FT                                {ECO:0000269|PubMed:8675656}.
FT                                /FTId=VAR_010730.
FT   VARIANT      55     55       C -> R (in CAFBN; hypofibrinogenemia;
FT                                heterozygous; decreased fibrinogen
FT                                complex assembly; no effect on fibrinogen
FT                                complex secretion).
FT                                {ECO:0000269|PubMed:25427968}.
FT                                /FTId=VAR_072721.
FT   VARIANT      66     66       S -> T.
FT                                /FTId=VAR_002398.
FT   VARIANT     129    129       R -> P (in CAFBN; hypofibrinogenemia;
FT                                heterozygous; no effect on fibrinogen
FT                                complex assembly; no effect on fibrinogen
FT                                complex secretion).
FT                                {ECO:0000269|PubMed:25427968}.
FT                                /FTId=VAR_072722.
FT   VARIANT     160    160       R -> S (in Lima).
FT                                {ECO:0000269|PubMed:1634621}.
FT                                /FTId=VAR_002399.
FT   VARIANT     184    184       C -> W (in CAFBN; hypofibrinogenemia;
FT                                heterozygous; impaired fibrinogen complex
FT                                assembly). {ECO:0000269|PubMed:25427968}.
FT                                /FTId=VAR_072723.
FT   VARIANT     331    331       T -> A (in dbSNP:rs6050).
FT                                {ECO:0000269|PubMed:10391209,
FT                                ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|Ref.3}.
FT                                /FTId=VAR_011610.
FT   VARIANT     446    446       K -> E (in dbSNP:rs6052).
FT                                {ECO:0000269|PubMed:10391209}.
FT                                /FTId=VAR_014168.
FT   VARIANT     453    453       S -> N (in Caracas-2; dbSNP:rs121909610).
FT                                {ECO:0000269|PubMed:1675636}.
FT                                /FTId=VAR_002400.
FT   VARIANT     456    456       T -> A (in dbSNP:rs2070031).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_011611.
FT   VARIANT     545    545       E -> V (in AMYL8; dbSNP:rs121909612).
FT                                /FTId=VAR_010731.
FT   VARIANT     573    573       R -> C (in DYSFIBRIN; fibrinogen Dusart/
FT                                Paris-5; dbSNP:rs121909613).
FT                                {ECO:0000269|PubMed:8473507}.
FT                                /FTId=VAR_002401.
FT   VARIANT     573    573       R -> L (in AMYL8; dbSNP:rs78506343).
FT                                {ECO:0000269|PubMed:8097946}.
FT                                /FTId=VAR_010732.
FT   CONFLICT    177    177       I -> V (in Ref. 4; BAF83248).
FT                                {ECO:0000305}.
FT   CONFLICT    215    216       SR -> RS (in Ref. 10; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    299    299       S -> G (in Ref. 10; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    304    304       S -> G (in Ref. 10; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    317    318       GT -> SG (in Ref. 11; AA sequence).
FT                                {ECO:0000305}.
FT   TURN         27     31       {ECO:0000244|PDB:1BBR}.
FT   STRAND       57     60       {ECO:0000244|PDB:3GHG}.
FT   STRAND       63     65       {ECO:0000244|PDB:3GHG}.
FT   HELIX        67     92       {ECO:0000244|PDB:3GHG}.
FT   HELIX        94    111       {ECO:0000244|PDB:3GHG}.
FT   HELIX       116    129       {ECO:0000244|PDB:3GHG}.
FT   TURN        133    135       {ECO:0000244|PDB:1FZA}.
FT   TURN        139    141       {ECO:0000244|PDB:1FZC}.
FT   HELIX       142    178       {ECO:0000244|PDB:1FZC}.
FT   TURN        179    183       {ECO:0000244|PDB:1FZC}.
FT   STRAND      184    186       {ECO:0000244|PDB:1RE3}.
FT   HELIX       195    209       {ECO:0000244|PDB:1FZC}.
FT   TURN        226    228       {ECO:0000244|PDB:3GHG}.
FT   STRAND      337    343       {ECO:0000244|PDB:4F27}.
FT   STRAND      582    587       {ECO:0000244|PDB:5CFA}.
FT   STRAND      673    681       {ECO:0000244|PDB:1FZD}.
FT   HELIX       689    694       {ECO:0000244|PDB:1FZD}.
FT   HELIX       711    718       {ECO:0000244|PDB:1FZD}.
FT   STRAND      723    729       {ECO:0000244|PDB:1FZD}.
FT   STRAND      735    744       {ECO:0000244|PDB:1FZD}.
FT   TURN        747    751       {ECO:0000244|PDB:1FZD}.
FT   STRAND      753    762       {ECO:0000244|PDB:1FZD}.
FT   TURN        765    768       {ECO:0000244|PDB:1FZD}.
FT   TURN        771    773       {ECO:0000244|PDB:1FZD}.
FT   HELIX       775    778       {ECO:0000244|PDB:1FZD}.
FT   STRAND      793    797       {ECO:0000244|PDB:1FZD}.
FT   HELIX       799    803       {ECO:0000244|PDB:1FZD}.
FT   STRAND      810    812       {ECO:0000244|PDB:1FZD}.
FT   STRAND      814    816       {ECO:0000244|PDB:1FZD}.
FT   STRAND      823    826       {ECO:0000244|PDB:1FZD}.
FT   HELIX       829    831       {ECO:0000244|PDB:1FZD}.
FT   STRAND      840    843       {ECO:0000244|PDB:1FZD}.
FT   HELIX       844    847       {ECO:0000244|PDB:1FZD}.
FT   STRAND      854    861       {ECO:0000244|PDB:1FZD}.
SQ   SEQUENCE   866 AA;  94973 MW;  EA73A81204D8AEC4 CRC64;
     MFSMRIVCLV LSVVGTAWTA DSGEGDFLAE GGGVRGPRVV ERHQSACKDS DWPFCSDEDW
     NYKCPSGCRM KGLIDEVNQD FTNRINKLKN SLFEYQKNNK DSHSLTTNIM EILRGDFSSA
     NNRDNTYNRV SEDLRSRIEV LKRKVIEKVQ HIQLLQKNVR AQLVDMKRLE VDIDIKIRSC
     RGSCSRALAR EVDLKDYEDQ QKQLEQVIAK DLLPSRDRQH LPLIKMKPVP DLVPGNFKSQ
     LQKVPPEWKA LTDMPQMRME LERPGGNEIT RGGSTSYGTG SETESPRNPS SAGSWNSGSS
     GPGSTGNRNP GSSGTGGTAT WKPGSSGPGS TGSWNSGSSG TGSTGNQNPG SPRPGSTGTW
     NPGSSERGSA GHWTSESSVS GSTGQWHSES GSFRPDSPGS GNARPNNPDW GTFEEVSGNV
     SPGTRREYHT EKLVTSKGDK ELRTGKEKVT SGSTTTTRRS CSKTVTKTVI GPDGHKEVTK
     EVVTSEDGSD CPEAMDLGTL SGIGTLDGFR HRHPDEAAFF DTASTGKTFP GFFSPMLGEF
     VSETESRGSE SGIFTNTKES SSHHPGIAEF PSRGKSSSYS KQFTSSTSYN RGDSTFESKS
     YKMADEAGSE ADHEGTHSTK RGHAKSRPVR DCDDVLQTHP SGTQSGIFNI KLPGSSKIFS
     VYCDQETSLG GWLLIQQRMD GSLNFNRTWQ DYKRGFGSLN DEGEGEFWLG NDYLHLLTQR
     GSVLRVELED WAGNEAYAEY HFRVGSEAEG YALQVSSYEG TAGDALIEGS VEEGAEYTSH
     NNMQFSTFDR DADQWEENCA EVYGGGWWYN NCQAANLNGI YYPGGSYDPR NNSPYEIENG
     VVWVSFRGAD YSLRAVRMKI RPLVTQ
//
